Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MaxCyte ( (MXCT) ) just unveiled an update.
MaxCyte, Inc. has announced its intention to cancel the trading of its ordinary shares on AIM, with plans to file a definitive proxy statement to seek stockholder approval for this delisting. The company aims to focus on its NASDAQ listing, and the move is part of a strategic decision to streamline its market presence, potentially impacting stakeholders by concentrating trading activities on a single exchange.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell engineering industry, providing platform technologies that advance the discovery, development, and commercialization of next-generation cell therapeutics. Their ExPERT platform, based on Flow Electroporation technology, supports the expanding cell therapy market and includes a range of instruments and proprietary processing assemblies.
YTD Price Performance: -34.57%
Average Trading Volume: 34,074
Technical Sentiment Signal: Buy
Current Market Cap: £230.5M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.